FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
“On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.”
Retired NY Police Officer Runs Boston Marathon 6 Months After Lung Cancer Surgery
“When Vinny O’Shaughnessy crossed the finish line at the Boston Marathon, he says he was the “happiest guy on earth.” Mostly happy it was over— each step of the 26.2 miles hurt because of some bruised ribs sustained in a fall while training — but also because even cancer couldn’t keep him from his goal.”
Preoperative Physical Dysfunction Characteristics and Influence Factors Among Elderly Patients with Early Lung Cancer: A Latent Class Analysis
“Conclusion: The variety of preoperative physical dysfunction seen in elderly patients with early lung cancer can be categorized into three latent classes. Medical professionals should create strategies for intervention for multiple patient populations with the goal of further enhancing their general state of life.”
Moffitt Researchers Discover New Therapeutic Target for Non-Small Cell Lung Cancer
TAMPA, Fla. — Non-small cell lung cancer accounts for nearly 85% of all lung cancer cases. Targeted immunotherapy is a common treatment, but it does not work for everyone. However, a new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies.”
New trials show promise for immune checkpoint blockers in early-stage lung cancer
“In a recent phase I trial published in the journal Cell Reports Medicine, researchers from Belgium administered a dendritic cell (DC) vaccine targeting patient-specific neoantigens to patients with resected non-small cell lung cancer (NSCLC). They found that the vaccine was viable and led to limited toxicity and systemic T-cell responses, with 50% of patients experiencing disease recurrence during the study.”
A Combination of Targeted Therapies Proves Effective Against Mutation-Driven Lung Cancer
“Combining targeted therapies known as tyrosine kinase inhibitors (TKIs) can be an effective way to treat a mutation-driven form of lung cancer in cases where tumors develop resistance to treatment and where cancer has spread to other parts of the body, a University of Colorado Cancer Center member reports. “This combination has not been studied very well before, and it really has shown some impressive results,” says Tejas Patil, MD, an assistant professor in the CU Division of Medical Oncology.”
Financial Strain, Quality of Life Top Unmet Needs in Lung Cancer Survivors
““Overall, our findings suggest that unmet needs are associated with QOL and financial toxicity and highlight the potential for targeted interventions that address these needs to improve QOL and financial toxicity among survivors of lung cancer,” they concluded. “Based on our findings of unmet needs and potential interventions to improve QOL and FT and on prior research including recommendations per the National Comprehensive Cancer Network survivorship guidelines, we propose a survivorship framework adapted from Nekhlyudov et al for survivors of lung cancer.””
Video:
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
“The robotic-assisted biopsy platform Ion is a “game-changer” for patients with lung cancer, as it provides a quicker, less invasive surgical method for conducting a lung biopsy, according to Richard Lazzaro, MD. In a conversation with CancerNetwork, Lazzaro, the chief of Thoracic Surgery at the Southern Region of RWJBarnabas Health, spoke about his experience with adopting the Ion robotic bronchoscopy platform for the early detection of lung cancer at Monmouth Medical Center. He highlighted how the tool may enable practices to acquire tissue and perform disease staging with fewer complications, which may particularly benefit those who plan to undergo induction chemotherapy or immunotherapy.”
Podcast: Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment
